Stryker Shares Rise After Commercial Launch of Mako Robotic Power System
By Grace Yoon
Shares of Stryker rose after the medical technology company said it commercially launched its Mako robotic power system for total knee replacement procedures.
The stock was up 5.1% to $332.99 in recent trading, but fell 5.3% since the start of the year.
Stryker said the system would provide surgeons with an intuitive handheld robotic experience, introducing its technology to a new customer segment of the orthopaedic market.
Vice President of Stryker's Mako and Enabling Technologies business Keith Evans said customer response during the limited market release has been exceptionally strong.
The new technology is equipped with Stryker's patented active adjustment technology and provides a familiar cutting experience for surgeons interested in adopting robotic technology while integrating easily into their existing surgical workflows, the company said.
Write to Grace Yoon at grace.yoon@wsj.com
(END) Dow Jones Newswires
July 16, 2026 11:14 ET (15:14 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States